美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

亞盛醫藥

42.47

+1.343.25%

盤後：42.470.00000.00%18:34 EDT

成交量：1.00萬

成交額：42.42萬

市值：39.48億

市盈率：-57.74

高：42.48

開：42.37

低：41.98

收：41.13

52周最高：48.45

52周最低：16.50

股本：9,296.34萬

流通股本：7,158.28萬

量比：0.89

換手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-0.7356

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：42.22

市盈率(LYR):-57.74

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

異動解讀 | 亞盛醫藥盤中大跌5.25%，生物醫藥板塊整體承壓

港股生物醫藥股震盪回調，歐康維視生物跌超15%，百奧賽圖、中國抗體跌超8.5%，亞盛醫藥跌超6%。

中金：維持亞盛醫藥-B(06855)跑贏行業評級升目標價至105港元

亞盛醫藥-B：耐立克放量迅速利生妥再加碼差異化佈局

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":42.47,"timestamp":1756497600000,"preClose":41.1327,"halted":0,"volume":10030,"hourTrading":{"tag":"盘后","latestPrice":42.47,"preClose":42.47,"latestTime":"18:34 EDT","volume":7,"amount":301.16,"timestamp":1756506858587},"delay":0,"floatShares":71582800,"shares":92963368,"eps":-0.735552,"marketStatus":"休市中","change":1.3373,"latestTime":"08-29 16:00:00 EDT","open":42.37,"high":42.48,"low":41.98,"amount":424157.42628,"amplitude":0.012156,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":41.1327,"preHourTrading":{"tag":"盘前","latestPrice":42.67,"preClose":41.81,"latestTime":"08:53 EDT","volume":405,"amount":17533.550385000002,"timestamp":1756472032284},"postHourTrading":{"tag":"盘后","latestPrice":42.47,"preClose":42.47,"latestTime":"18:34 EDT","volume":7,"amount":301.16,"timestamp":1756506858587},"volumeRatio":0.8923646328226481},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":0.8923646328226481,"shares":92963368,"dividePrice":0,"high":42.48,"amplitude":0.012156,"preClose":41.1327,"low":41.98,"week52Low":16.5,"pbRate":"42.22","psRate":"71.98","week52High":48.45,"institutionHeld":0,"latestPrice":42.47,"eps":-0.735552,"divideRate":0,"volume":10030,"delay":0,"ttmEps":-0.735552,"open":42.37,"prevYearClose":17.25,"prevWeekClose":47.9,"prevMonthClose":37,"prevQuarterClose":39.375,"fiveDayClose":47.9,"twentyDayClose":37.2,"sixtyDayClose":28.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-08-29","current":-24.396919,"percent":0.986486,"low":-76.454813,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"high":-23.707409,"avg":-43.114344,"sd":13.979917,"marketCap":3966417985.85},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85}],"updateTime":1756679608263},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1136407164","title":"異動解讀 | 亞盛醫藥盤中大跌5.25%，生物醫藥板塊整體承壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1136407164","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136407164?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:32","pubTimestamp":1756128779,"startTime":"0","endTime":"0","summary":"8月25日周一盘中，亚盛医药股价出现大幅下跌，跌幅达5.25%，引发市场关注。此次下跌主要受到生物医药板块整体走弱的影响。其中，欧康维视生物跌幅超过15%，百奥赛图和中国抗体跌幅均超过8.5%，亚盛医药跌幅超过6%。这一行业性下跌趋势可能是导致亚盛医药股价下跌的主要原因。值得注意的是，尽管股价下跌，但亚盛医药近期获得了积极的分析师评价。中金公司维持亚盛医药\"跑赢行业\"评级，并将目标价上调19.3%至105港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2562291249","title":"港股生物醫藥股震盪回調，歐康維視生物跌超15%，百奧賽圖、中國抗體跌超8.5%，亞盛醫藥跌超6%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291249","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562291249?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 10:51","pubTimestamp":1756090312,"startTime":"0","endTime":"0","summary":"港股生物医药股震荡回调，欧康维视生物跌超15%，百奥赛图、中国抗体跌超8.5%，亚盛医药跌超6%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25105152660744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HSCEI","BK1574","BK4139","161726","YANG","HSTECH","BK4614","AAPG","399441","BK1161","03681","07226"],"gpt_icon":0},{"id":"2562291614","title":"中金：維持亞盛醫藥-B(06855)跑贏行業評級 升目標價至105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562291614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562291614?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 10:39","pubTimestamp":1756089589,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B2025年/2026年归母净利润预测不变，维持跑赢行业评级，考虑到GLORA-4进展，新适应症空间可见度提升，根据DCF模型，上调目标价19.3%至105港币，离当前股价有15.8%的上行空间。公司1H25收入2.34亿元，主要由于去年同期产生授权收入，1H25业绩符合该行预期。该行认为MDS患者人群广泛，一线治疗存在较大未满足需求，公司利生妥这一布局有望加码其差异化优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG"],"gpt_icon":0},{"id":"2561250107","title":"亞盛醫藥-B：耐立克放量迅速 利生妥再加碼差異化佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2561250107","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561250107?lang=zh_tw&edition=fundamental","pubTime":"2025-08-24 00:00","pubTimestamp":1755964800,"startTime":"0","endTime":"0","summary":"发展趋势耐立克新适应进入医保带来上半年商业化收入高速增长，下半年利沙妥克拉获批上市有望贡献新增长点。根据公司公告，截至公告日，利生妥是国际唯一正推进中高危MDS 注册III 期临床的Bcl-2 抑制剂，有望打破该领域长期空白。此前2025ASCO 上发表的数据表明，利生妥联合阿扎胞苷治疗初治MDS 的ORR 达到75%，且安全性良好。我们认为MDS 患者人群广泛，一线治疗存在较大未满足需求，公司利生妥这一布局有望加码其差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250824143619a6f81ba9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250824143619a6f81ba9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0}],"pageSize":4,"totalPage":45,"pageCount":1,"totalSize":177,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AAPG\",params:#limit:6,delay:false,,,undefined,":[]}}